PharmaShots | Incisive News in 3 Shots

Subscribe Now

infliximab

Cardinal Health Reports the Discontinuation of Biosimilar Infliximab & Switched Back to Remicade in the VA Study for Inflammatory Conditions

Cardinal Health Reports the Discontinuation of Biosimilar Infliximab & Switched Back to Remicade in the VA Study for Inflammatory...

February 12, 2022

Celltrion's Remsima SC (infliximab- CT-P13) Receives the EC's MAA for Additional Five Indications

Celltrion's Remsima SC (infliximab- CT-P13) Receives the EC's MAA for Additional Five Indications

July 27, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us